295 related articles for article (PubMed ID: 28434191)
1. The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures.
Richards TM; Hurley T; Grove L; Harrington KJ; Carpenter GH; Proctor GB; Nutting CM
Oral Dis; 2017 Oct; 23(7):990-1000. PubMed ID: 28434191
[TBL] [Abstract][Full Text] [Related]
2. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
3. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
[TBL] [Abstract][Full Text] [Related]
4. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
[TBL] [Abstract][Full Text] [Related]
5. Objective and subjective assessment of xerostomia in patients of locally advanced head-and-neck cancers treated by intensity-modulated radiotherapy.
Lal P; Nautiyal V; Verma M; Yadav R; Maria Das KJ; Kumar S
J Cancer Res Ther; 2018; 14(6):1196-1201. PubMed ID: 30488829
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
[TBL] [Abstract][Full Text] [Related]
7. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
8. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
[TBL] [Abstract][Full Text] [Related]
9. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
[TBL] [Abstract][Full Text] [Related]
10. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life.
Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF
Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066
[TBL] [Abstract][Full Text] [Related]
11. Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control.
Chajon E; Lafond C; Louvel G; Castelli J; Williaume D; Henry O; Jégoux F; Vauléon E; Manens JP; Le Prisé E; de Crevoisier R
Radiat Oncol; 2013 May; 8():132. PubMed ID: 23721062
[TBL] [Abstract][Full Text] [Related]
12. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
[TBL] [Abstract][Full Text] [Related]
13. Reducing Xerostomia by Comprehensive Protection of Salivary Glands in Intensity-Modulated Radiation Therapy with Helical Tomotherapy Technique for Head-and-Neck Cancer Patients: A Prospective Observational Study.
Teng F; Fan W; Luo Y; Ju Z; Gong H; Ge R; Tong F; Zhang X; Ma L
Biomed Res Int; 2019; 2019():2401743. PubMed ID: 31380414
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiation therapy and xerostomia.
Chambers MS; Weber RS; Garden AS
J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
[TBL] [Abstract][Full Text] [Related]
15. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
[TBL] [Abstract][Full Text] [Related]
16. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
17. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
[TBL] [Abstract][Full Text] [Related]
18. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
[TBL] [Abstract][Full Text] [Related]
19. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
Beetz I; Schilstra C; van der Schaaf A; van den Heuvel ER; Doornaert P; van Luijk P; Vissink A; van der Laan BF; Leemans CR; Bijl HP; Christianen ME; Steenbakkers RJ; Langendijk JA
Radiother Oncol; 2012 Oct; 105(1):101-6. PubMed ID: 22516776
[TBL] [Abstract][Full Text] [Related]
20. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
